[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @AVDB2171 Alan Vanderborght Alan Vanderborght posts on X about $52b, acquisition, novo, $439b the most. They currently have XXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::1686081948270182401/interactions)  - X Week XXXXXX +1,700% - X Month XXXXXX -XX% ### Mentions: XX [#](/creator/twitter::1686081948270182401/posts_active)  - X Week XX +52% - X Month XXX +46% ### Followers: XXX [#](/creator/twitter::1686081948270182401/followers)  - X Week XXX +10% - X Month XXX +41% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1686081948270182401/influencer_rank)  ### Social Influence [#](/creator/twitter::1686081948270182401/influence) --- **Social category influence** [finance](/list/finance) XXXX% [stocks](/list/stocks) XXXXX% **Social topic influence** [$52b](/topic/$52b) #1, [acquisition](/topic/acquisition) #341, [novo](/topic/novo) 4.65%, [$439b](/topic/$439b) 2.33%, [launches](/topic/launches) 2.33%, [$11b](/topic/$11b) 2.33%, [$37b](/topic/$37b) 2.33%, [asia](/topic/asia) 2.33%, [$18m](/topic/$18m) 2.33%, [$109b](/topic/$109b) XXXX% ### Top Social Posts [#](/creator/twitter::1686081948270182401/posts) --- Top posts by engagements in the last XX hours "#3: Prolia/Xgeva (Amgen) - $4.39B U.S. sales Amgen long a leader in biosimilars now faces denosumab biosimilars itself. Sandoz launches May 31st Celltrion June 1st. It's a reminder that no franchise is immune moats in this industry are always temporary" [X Link](https://x.com/AVDB2171/status/1961116761283334633) [@AVDB2171](/creator/x/AVDB2171) 2025-08-28T17:20Z XXX followers, 1294 engagements "Glenmark just signed a $1.1B licensing deal with Chinas Hengrui Pharma. No U.S. or EU rights. No Big Pharma intermediaries. Just two emerging-market leaders building a new model for global biotech. Heres why this deal matters more than it seems:" [X Link](https://x.com/AVDB2171/status/1978109812622893504) [@AVDB2171](/creator/x/AVDB2171) 2025-10-14T14:45Z XXX followers, 9984 engagements "For years antibodydrug conjugates (ADCs) were the Wests domain. Then came Enhertu: AstraZeneca and Daiichis $3.7B blockbuster proving how powerful targeted payloads could be. Now Asia wants in on the next wave" [X Link](https://x.com/AVDB2171/status/1978109824954175577) [@AVDB2171](/creator/x/AVDB2171) 2025-10-14T14:45Z XXX followers, XXX engagements "Deal terms: $18M upfront $1.09B in milestones Royalties on sales For Glenmark: a credible oncology entry. For Hengrui: expansion without overextending. Everyone plays to their strengths" [X Link](https://x.com/AVDB2171/status/1978110044341493780) [@AVDB2171](/creator/x/AVDB2171) 2025-10-14T14:46Z XXX followers, XXX engagements "This isnt Hengruis first major partnership. In the past XX months: $12B+ multi-asset deal with GSK $2B cardiovascular partnership with Merck Chinas innovators arent copying anymore theyre exporting" [X Link](https://x.com/AVDB2171/status/1978110110942855251) [@AVDB2171](/creator/x/AVDB2171) 2025-10-14T14:46Z XXX followers, XX engagements "AstraZeneca just made a $555M AI pact with a San Francisco biotech. No clinical programs. No approved drugs. Just ONE thing that made every boardroom take notice. Here's why it could reshape how Big Pharma discovers therapies:" [X Link](https://x.com/AVDB2171/status/1979189446655512797) [@AVDB2171](/creator/x/AVDB2171) 2025-10-17T14:15Z XXX followers, 6450 engagements "AstraZeneca has been steadily expanding its AI footprint. In 2025 alone it announced: a $5.3B AI deal with CSPC a $200M oncology partnership with Tempus & Pathos AI And now they just made one of their boldest platform bets yet:" [X Link](https://x.com/AVDB2171/status/1979189461654344056) [@AVDB2171](/creator/x/AVDB2171) 2025-10-17T14:15Z XXX followers, XXX engagements "Novo Nordisk just doubled down on MASH with a $5.2B acquisition that could define its post-GLP-1 era. This isnt diversification. Its focus. Heres why the deal may shape the next decade of cardiometabolic medicine:" [X Link](https://x.com/AVDB2171/status/1980276585807974458) [@AVDB2171](/creator/x/AVDB2171) 2025-10-20T14:15Z XXX followers, 10.1K engagements "Novo Nordisk just made its first major move under new CEO Mike Doustdar: A $5.2B acquisition of Akero Therapeutics a U.S. biotech developing advanced therapies for liver disease. The deal terms:" [X Link](https://x.com/AVDB2171/status/1980276600244674591) [@AVDB2171](/creator/x/AVDB2171) 2025-10-20T14:15Z XXX followers, XXX engagements "$4.7B upfront at $54/share $500M milestone tied to FDA approval by mid-2031 Financed through debt Expected to close by year-end But the strategic logic matters more than the structure" [X Link](https://x.com/AVDB2171/status/1980276615289708991) [@AVDB2171](/creator/x/AVDB2171) 2025-10-20T14:15Z XXX followers, XX engagements "Novo called it an important building block for future growth. Analysts see it as a critical asset for Novos metabolic franchise. MASH sits at the intersection of obesity diabetes and liver disease all areas where Novo already leads with its GLP-1 portfolio" [X Link](https://x.com/AVDB2171/status/1980276642699481404) [@AVDB2171](/creator/x/AVDB2171) 2025-10-20T14:15Z XXX followers, XX engagements "So this deal isnt diversification. Its an expansion of Novos metabolic ecosystem. The competitive landscape is heating up" [X Link](https://x.com/AVDB2171/status/1980276658289664436) [@AVDB2171](/creator/x/AVDB2171) 2025-10-20T14:15Z XXX followers, XX engagements "Novo shares have risen XX% since Doustdars appointment though still down XX% YTD. Investors remain cautious but the market rewarded Akero with a XX% spike on announcement day. The signal is clear: high conviction in the asset class" [X Link](https://x.com/AVDB2171/status/1980276741248811247) [@AVDB2171](/creator/x/AVDB2171) 2025-10-20T14:15Z XXX followers, XX engagements "3 Takeaways for Biopharma Leaders: Depth Diversification. Novo stayed in its lane and went deeper. De-risked assets still move the needle when timed to patent cliffs. MASH is the next cardiometabolic frontier: whoever wins payer access first wins the decade" [X Link](https://x.com/AVDB2171/status/1980276753617875311) [@AVDB2171](/creator/x/AVDB2171) 2025-10-20T14:15Z XXX followers, XX engagements "This deal reinforces Novos playbook: focus beats diversification. Doustdars first move shows conviction acquiring where they already lead not chasing new categories. Strategic continuity often outperforms reinvention" [X Link](https://x.com/AVDB2171/status/1980276765437440430) [@AVDB2171](/creator/x/AVDB2171) 2025-10-20T14:15Z XXX followers, XX engagements "Biotech deal flow and market trends are complex but approachable with the right guidance. At we support leaders navigating these challenges with authentic insightful content. Follow me @AVDB2171 for more on biotech M&A market shifts & strategy" [X Link](https://x.com/AVDB2171/status/1980276789059686834) [@AVDB2171](/creator/x/AVDB2171) 2025-10-20T14:15Z XXX followers, XX engagements "Media Used:" [X Link](https://x.com/AVDB2171/status/1980276801118326922) [@AVDB2171](/creator/x/AVDB2171) 2025-10-20T14:15Z XXX followers, XX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Alan Vanderborght posts on X about $52b, acquisition, novo, $439b the most. They currently have XXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.
Social category influence finance XXXX% stocks XXXXX%
Social topic influence $52b #1, acquisition #341, novo 4.65%, $439b 2.33%, launches 2.33%, $11b 2.33%, $37b 2.33%, asia 2.33%, $18m 2.33%, $109b XXXX%
Top posts by engagements in the last XX hours
"#3: Prolia/Xgeva (Amgen) - $4.39B U.S. sales Amgen long a leader in biosimilars now faces denosumab biosimilars itself. Sandoz launches May 31st Celltrion June 1st. It's a reminder that no franchise is immune moats in this industry are always temporary"
X Link @AVDB2171 2025-08-28T17:20Z XXX followers, 1294 engagements
"Glenmark just signed a $1.1B licensing deal with Chinas Hengrui Pharma. No U.S. or EU rights. No Big Pharma intermediaries. Just two emerging-market leaders building a new model for global biotech. Heres why this deal matters more than it seems:"
X Link @AVDB2171 2025-10-14T14:45Z XXX followers, 9984 engagements
"For years antibodydrug conjugates (ADCs) were the Wests domain. Then came Enhertu: AstraZeneca and Daiichis $3.7B blockbuster proving how powerful targeted payloads could be. Now Asia wants in on the next wave"
X Link @AVDB2171 2025-10-14T14:45Z XXX followers, XXX engagements
"Deal terms: $18M upfront $1.09B in milestones Royalties on sales For Glenmark: a credible oncology entry. For Hengrui: expansion without overextending. Everyone plays to their strengths"
X Link @AVDB2171 2025-10-14T14:46Z XXX followers, XXX engagements
"This isnt Hengruis first major partnership. In the past XX months: $12B+ multi-asset deal with GSK $2B cardiovascular partnership with Merck Chinas innovators arent copying anymore theyre exporting"
X Link @AVDB2171 2025-10-14T14:46Z XXX followers, XX engagements
"AstraZeneca just made a $555M AI pact with a San Francisco biotech. No clinical programs. No approved drugs. Just ONE thing that made every boardroom take notice. Here's why it could reshape how Big Pharma discovers therapies:"
X Link @AVDB2171 2025-10-17T14:15Z XXX followers, 6450 engagements
"AstraZeneca has been steadily expanding its AI footprint. In 2025 alone it announced: a $5.3B AI deal with CSPC a $200M oncology partnership with Tempus & Pathos AI And now they just made one of their boldest platform bets yet:"
X Link @AVDB2171 2025-10-17T14:15Z XXX followers, XXX engagements
"Novo Nordisk just doubled down on MASH with a $5.2B acquisition that could define its post-GLP-1 era. This isnt diversification. Its focus. Heres why the deal may shape the next decade of cardiometabolic medicine:"
X Link @AVDB2171 2025-10-20T14:15Z XXX followers, 10.1K engagements
"Novo Nordisk just made its first major move under new CEO Mike Doustdar: A $5.2B acquisition of Akero Therapeutics a U.S. biotech developing advanced therapies for liver disease. The deal terms:"
X Link @AVDB2171 2025-10-20T14:15Z XXX followers, XXX engagements
"$4.7B upfront at $54/share $500M milestone tied to FDA approval by mid-2031 Financed through debt Expected to close by year-end But the strategic logic matters more than the structure"
X Link @AVDB2171 2025-10-20T14:15Z XXX followers, XX engagements
"Novo called it an important building block for future growth. Analysts see it as a critical asset for Novos metabolic franchise. MASH sits at the intersection of obesity diabetes and liver disease all areas where Novo already leads with its GLP-1 portfolio"
X Link @AVDB2171 2025-10-20T14:15Z XXX followers, XX engagements
"So this deal isnt diversification. Its an expansion of Novos metabolic ecosystem. The competitive landscape is heating up"
X Link @AVDB2171 2025-10-20T14:15Z XXX followers, XX engagements
"Novo shares have risen XX% since Doustdars appointment though still down XX% YTD. Investors remain cautious but the market rewarded Akero with a XX% spike on announcement day. The signal is clear: high conviction in the asset class"
X Link @AVDB2171 2025-10-20T14:15Z XXX followers, XX engagements
"3 Takeaways for Biopharma Leaders: Depth Diversification. Novo stayed in its lane and went deeper. De-risked assets still move the needle when timed to patent cliffs. MASH is the next cardiometabolic frontier: whoever wins payer access first wins the decade"
X Link @AVDB2171 2025-10-20T14:15Z XXX followers, XX engagements
"This deal reinforces Novos playbook: focus beats diversification. Doustdars first move shows conviction acquiring where they already lead not chasing new categories. Strategic continuity often outperforms reinvention"
X Link @AVDB2171 2025-10-20T14:15Z XXX followers, XX engagements
"Biotech deal flow and market trends are complex but approachable with the right guidance. At we support leaders navigating these challenges with authentic insightful content. Follow me @AVDB2171 for more on biotech M&A market shifts & strategy"
X Link @AVDB2171 2025-10-20T14:15Z XXX followers, XX engagements
"Media Used:"
X Link @AVDB2171 2025-10-20T14:15Z XXX followers, XX engagements
/creator/twitter::AVDB2171